Matthew Taylor
Stock Analyst at Jefferies
(3.23)
# 1,017
Out of 4,650 analysts
178
Total ratings
58.72%
Success rate
8.58%
Average return
Main Sectors:
Stocks Rated by Matthew Taylor
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABT Abbott Laboratories | Maintains: Hold | $120 → $125 | $114.07 | +9.58% | 12 | Oct 17, 2024 | |
| EW Edwards Lifesciences | Downgrades: Hold | $85 → $70 | $68.52 | +2.16% | 19 | Sep 18, 2024 | |
| PODD Insulet | Maintains: Neutral | $211 → $223 | $233.37 | -4.44% | 14 | Aug 9, 2024 | |
| INMD InMode | Downgrades: Hold | $21 → $19 | $17.98 | +5.67% | 6 | Jul 23, 2024 | |
| MDT Medtronic | Maintains: Sell | $75 → $76 | $90.60 | -16.11% | 17 | May 24, 2024 | |
| ALUR Allurion Technologies | Initiates: Buy | $5 | $0.75 | +563.04% | 1 | Feb 9, 2024 | |
| MASI Masimo | Downgrades: Hold | $107 → $121 | $140.71 | -14.01% | 9 | Jan 30, 2024 | |
| OBIO Orchestra BioMed Holdings | Initiates: Buy | $14 | $5.87 | +138.50% | 1 | Jan 19, 2024 | |
| GEHC GE HealthCare Technologies | Initiates: Hold | $80 | $85.93 | -6.90% | 1 | Nov 30, 2023 | |
| TNDM Tandem Diabetes Care | Maintains: Buy | $47 → $45 | $32.75 | +37.40% | 2 | Oct 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underperform | $0.5 | $0.34 | +45.01% | 1 | Jul 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $58 → $53 | $19.32 | +174.33% | 2 | Jul 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $22 → $24 | $13.15 | +82.51% | 2 | May 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $320 → $345 | $356.01 | -3.09% | 14 | May 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Hold | $115 → $130 | $103.60 | +25.48% | 8 | Mar 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $230 | $208.74 | +10.18% | 1 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $12.27 | +63.00% | 1 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $75 | $70.24 | +6.78% | 1 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $85 | $63.76 | +33.31% | 1 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $75 | $74.20 | +1.08% | 7 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $245 | $246.83 | -0.74% | 7 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $88 | $42.56 | +106.77% | 1 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $62 | $36.01 | +72.17% | 8 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $210 | $236.63 | -11.25% | 1 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $5.27 | +127.70% | 1 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $125 | $72.10 | +73.37% | 12 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $84.76 | -41.01% | 1 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $210 | $510.88 | -58.89% | 12 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underperform | $31 | $4.91 | +531.36% | 5 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $96 | $53.16 | +80.59% | 3 | Feb 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $7 | $1.89 | +270.37% | 1 | Dec 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $266 | $238.91 | +11.34% | 4 | May 13, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $17 → $16 | $6.75 | +137.04% | 2 | Jul 19, 2017 |
Abbott Laboratories
Oct 17, 2024
Maintains: Hold
Price Target: $120 → $125
Current: $114.07
Upside: +9.58%
Edwards Lifesciences
Sep 18, 2024
Downgrades: Hold
Price Target: $85 → $70
Current: $68.52
Upside: +2.16%
Insulet
Aug 9, 2024
Maintains: Neutral
Price Target: $211 → $223
Current: $233.37
Upside: -4.44%
InMode
Jul 23, 2024
Downgrades: Hold
Price Target: $21 → $19
Current: $17.98
Upside: +5.67%
Medtronic
May 24, 2024
Maintains: Sell
Price Target: $75 → $76
Current: $90.60
Upside: -16.11%
Allurion Technologies
Feb 9, 2024
Initiates: Buy
Price Target: $5
Current: $0.75
Upside: +563.04%
Masimo
Jan 30, 2024
Downgrades: Hold
Price Target: $107 → $121
Current: $140.71
Upside: -14.01%
Orchestra BioMed Holdings
Jan 19, 2024
Initiates: Buy
Price Target: $14
Current: $5.87
Upside: +138.50%
GE HealthCare Technologies
Nov 30, 2023
Initiates: Hold
Price Target: $80
Current: $85.93
Upside: -6.90%
Tandem Diabetes Care
Oct 2, 2023
Maintains: Buy
Price Target: $47 → $45
Current: $32.75
Upside: +37.40%
Jul 19, 2023
Initiates: Underperform
Price Target: $0.5
Current: $0.34
Upside: +45.01%
Jul 12, 2023
Upgrades: Buy
Price Target: $58 → $53
Current: $19.32
Upside: +174.33%
May 24, 2023
Maintains: Hold
Price Target: $22 → $24
Current: $13.15
Upside: +82.51%
May 2, 2023
Maintains: Buy
Price Target: $320 → $345
Current: $356.01
Upside: -3.09%
Mar 31, 2023
Upgrades: Hold
Price Target: $115 → $130
Current: $103.60
Upside: +25.48%
Oct 12, 2022
Initiates: Buy
Price Target: $230
Current: $208.74
Upside: +10.18%
Oct 12, 2022
Initiates: Buy
Price Target: $20
Current: $12.27
Upside: +63.00%
Oct 12, 2022
Initiates: Hold
Price Target: $75
Current: $70.24
Upside: +6.78%
Oct 12, 2022
Initiates: Hold
Price Target: $85
Current: $63.76
Upside: +33.31%
Oct 12, 2022
Initiates: Buy
Price Target: $75
Current: $74.20
Upside: +1.08%
Oct 12, 2022
Initiates: Hold
Price Target: $245
Current: $246.83
Upside: -0.74%
Oct 12, 2022
Initiates: Buy
Price Target: $88
Current: $42.56
Upside: +106.77%
Oct 12, 2022
Initiates: Hold
Price Target: $62
Current: $36.01
Upside: +72.17%
Oct 12, 2022
Initiates: Hold
Price Target: $210
Current: $236.63
Upside: -11.25%
Oct 12, 2022
Initiates: Buy
Price Target: $12
Current: $5.27
Upside: +127.70%
Oct 12, 2022
Initiates: Buy
Price Target: $125
Current: $72.10
Upside: +73.37%
Oct 12, 2022
Initiates: Buy
Price Target: $50
Current: $84.76
Upside: -41.01%
Oct 12, 2022
Initiates: Hold
Price Target: $210
Current: $510.88
Upside: -58.89%
Oct 12, 2022
Initiates: Underperform
Price Target: $31
Current: $4.91
Upside: +531.36%
Feb 24, 2022
Upgrades: Buy
Price Target: $96
Current: $53.16
Upside: +80.59%
Dec 17, 2021
Initiates: Neutral
Price Target: $7
Current: $1.89
Upside: +270.37%
May 13, 2019
Upgrades: Overweight
Price Target: $266
Current: $238.91
Upside: +11.34%
Jul 19, 2017
Maintains: Equal-Weight
Price Target: $17 → $16
Current: $6.75
Upside: +137.04%